Another phase I trial by the DFCI explores the efficacy of CIML NK cells in patients with renal cell carcinoma and urothelial carcinoma, assessing IL-2’s role in augmenting NK cell-mediated tumor clearance [136]. The gene discussed is IL2; the disease is neoplasm.